Levodopa is effective for the motor symptoms of Parkinson's disease (PD), but is associated with motor fluctuations and dyskinesia. Many patients require add-on therapy to improve motor fluctuations without exacerbating dyskinesia. The objective of this Phase III, multicenter, double-blind, placebo-controlled, parallel-group study was to evaluate the efficacy and safety of safinamide, an α-aminoamide with dopaminergic and nondopaminergic mechanisms, as add-on to l-dopa in the treatment of patients with PD and motor fluctuations. Patients were randomized to oral safinamide 100 mg/day (n = 224), 50 mg/day (n = 223), or placebo (n = 222) for 24 weeks. The primary endpoint was total on time with no or nontroublesome dyskinesia (assessed using the Hauser patient diaries). Secondary endpoints included off time, Unified Parkinson's Disease Rating Scale (UPDRS) Part III (motor) scores, and Clinical Global Impression-Change (CGI-C). At week 24, mean ± SD increases in total on time with no or nontroublesome dyskinesia were 1.36 ± 2.625 hours for safinamide 100 mg/day, 1.37 ± 2.745 hours for safinamide 50 mg/day, and 0.97 ± 2.375 hours for placebo. Least squares means differences in both safinamide groups were significantly higher versus placebo. Improvements in off time, UPDRS Part III, and CGI-C were significantly greater in both safinamide groups versus placebo. There were no significant between-group differences for incidences of treatment-emergent adverse events (TEAEs) or TEAEs leading to discontinuation. The addition of safinamide 50 mg/day or 100 mg/day to l-dopa in patients with PD and motor fluctuations significantly increased total on time with no or nontroublesome dyskinesia, decreased off time, and improved parkinsonism, indicating that safinamide improves motor symptoms and parkinsonism without worsening dyskinesia.

Borgohain, R., Szasz, J., Stanzione, P., Meshram, C., Bhatt, M., Chirilineau, D., et al. (2014). Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. MOVEMENT DISORDERS, 29(2), 229-237 [10.1002/mds.25751].

Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations

STANZIONE, PAOLO;
2014-02-01

Abstract

Levodopa is effective for the motor symptoms of Parkinson's disease (PD), but is associated with motor fluctuations and dyskinesia. Many patients require add-on therapy to improve motor fluctuations without exacerbating dyskinesia. The objective of this Phase III, multicenter, double-blind, placebo-controlled, parallel-group study was to evaluate the efficacy and safety of safinamide, an α-aminoamide with dopaminergic and nondopaminergic mechanisms, as add-on to l-dopa in the treatment of patients with PD and motor fluctuations. Patients were randomized to oral safinamide 100 mg/day (n = 224), 50 mg/day (n = 223), or placebo (n = 222) for 24 weeks. The primary endpoint was total on time with no or nontroublesome dyskinesia (assessed using the Hauser patient diaries). Secondary endpoints included off time, Unified Parkinson's Disease Rating Scale (UPDRS) Part III (motor) scores, and Clinical Global Impression-Change (CGI-C). At week 24, mean ± SD increases in total on time with no or nontroublesome dyskinesia were 1.36 ± 2.625 hours for safinamide 100 mg/day, 1.37 ± 2.745 hours for safinamide 50 mg/day, and 0.97 ± 2.375 hours for placebo. Least squares means differences in both safinamide groups were significantly higher versus placebo. Improvements in off time, UPDRS Part III, and CGI-C were significantly greater in both safinamide groups versus placebo. There were no significant between-group differences for incidences of treatment-emergent adverse events (TEAEs) or TEAEs leading to discontinuation. The addition of safinamide 50 mg/day or 100 mg/day to l-dopa in patients with PD and motor fluctuations significantly increased total on time with no or nontroublesome dyskinesia, decreased off time, and improved parkinsonism, indicating that safinamide improves motor symptoms and parkinsonism without worsening dyskinesia.
feb-2014
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/26 - NEUROLOGIA
English
Con Impact Factor ISI
Severity of Illness Index; Levodopa; Alanine; Double-Blind Method; MAO-B inhibitor; Dose-Response Relationship, Drug; Humans; safinamide; Activities of Daily Living; Aged; Antiparkinson Agents; Benzylamines; Parkinson Disease; Motor Activity; Middle Aged; Follow-Up Studies; dyskinesia; Male; Female
Borgohain, R., Szasz, J., Stanzione, P., Meshram, C., Bhatt, M., Chirilineau, D., et al. (2014). Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. MOVEMENT DISORDERS, 29(2), 229-237 [10.1002/mds.25751].
Borgohain, R; Szasz, J; Stanzione, P; Meshram, C; Bhatt, M; Chirilineau, D; Stocchi, F; Lucini, V; Giuliani, R; Forrest, E; Rice, P; Anand, R; Sahadulla, M; Kardan, U; Keshava, B; Kishore, A; Kothari, S; Krishna Murthy, J; Kumar, S; Pal, P; Mehta, N; Meshram, C; Prabhakar, S; Prabhakar, S; Pradhan, S; Roy, A; Sankhla, C; Sethi, P; Shah, A; Shankar, N; Shukla, R; Sowani, A; Srinivasa, R; Varma, M; Vasudevan, D; Sreenivas, P; Velmurugendran, C; Vijayan, K; Bajenaru, O; Bulboaca, A; Campeanu, A; Chirileanu, D; Muresanu, D; Panea, C; Popescu, C; Simu, M; Szasz, J; Ticmeanu, M; Avarello, T; Bonuccelli, U; Eleopra, R; Onofrj, M; Quatrale, R; Stanzione, P; Stocchi, F
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
2.pdf

solo utenti autorizzati

Descrizione: Articolo principale
Licenza: Copyright dell'editore
Dimensione 412.69 kB
Formato Adobe PDF
412.69 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/100967
Citazioni
  • ???jsp.display-item.citation.pmc??? 85
  • Scopus 244
  • ???jsp.display-item.citation.isi??? 195
social impact